Skip to main content
Premium Trial:

Request an Annual Quote

Waters to Pay Agilent $6.1M to Settle HPLC Patent-Infringement Suit in UK

NEW YORK, Feb. 17 (GenomeWeb News) - Waters will pay Agilent a one-time payment of ₤3.5 million ($6.1 million) as part of a settlement agreement to resolve a patent-infringement suit involving high performance liquid chromatography technology.

 

In 2002, Waters stopped using a portion of the pump technology used in its Alliance HPLC instruments as a result of a patent infringement suit was brought before a court in the United Kingdom.

 

As a result of the settlement, Waters has revised downward its fourth-quarter 2005 and full-year 2005 earnings results that were previously reported on Jan. 24 to include a pre-tax $3.1 million for provision of damages and estimated remaining costs related to the suit.

 

The revision results in a reduction of earnings per diluted share for the fourth quarter to $0.69 from $0.71. For the full year 2005, the revision results in a reduction of earnings per diluted share to $1.74 from $1.76.

 

Other patent infringement suits between Waters and Agilent, similar to the one in the UK, are pending in Franceand Germany. Waters said it believes that damages from those suits are "unlikely to be materially different from amounts previously recorded."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.